Overview

Safety and Efficacy of Medications COVID-19

Status:
Completed
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
We performed a quasi-experimental open-label pragmatic study alternating standard of care (SOC) and oral bedtime melatonin (OBM) at different high doses over 4 consecutive time periods enrolling all consecutive RT-PCR SARS-CoV-2 severe Covid-19 admissions.
Phase:
N/A
Details
Lead Sponsor:
Hospital San Carlos, Madrid
Treatments:
Melatonin